Policy Developments - The National Medical Insurance Administration has issued a three-year action plan to enhance the efficiency of medical insurance fund settlement, aiming to complete annual settlements by March 31 each year starting in 2028, with settlement funds accounting for about 3% of the annual medical insurance fund allocation [2] Medical Device Approvals - Jiukang Bio has received a medical device registration certificate for its fructosamine testing kit, which is expected to enhance its product line in the in vitro diagnostic sector [5] - Yihuilong has obtained registration for its anti-phosphatidylserine/prothrombin IgM and IgG antibody testing kits, which will expand its automated chemiluminescence product line [6] - Kangzheng Pharmaceutical's oral JAK1 inhibitor, Povorcitinib, has been included in the "Breakthrough Therapy" list for treating non-segmental vitiligo in adults [7] Capital Market Activities - Fosun Pharma plans to invest a total of 1.412 billion yuan in Green Valley Pharmaceutical, acquiring a 53% stake through its subsidiary [9] - Paig Bio-Medical has announced a further extension of the lock-up period for cornerstone investors until April 30, 2026, and is raising approximately 296 million HKD for various strategic initiatives [10][11] Industry Developments - Nanjing has established a medical health merger and acquisition equity investment fund with a total investment of 800 million yuan, focusing on equity investment and asset management [13] - Zhenghai Bio has signed a 12 million yuan technical development contract with the Chinese Academy of Agricultural Sciences for the research and development of recombinant type III collagen products [14] - MicroPort Robotics has established a new medical technology company with a registered capital of 15 million yuan, focusing on the development and manufacturing of service robots [15] Public Opinion Alerts - Tongrentang has responded to allegations of false labeling regarding its Antarctic krill oil product, initiating legal action against the involved parties to protect consumer rights [17]

Policy Developments - The National Healthcare Security Administration (NHSA) has issued a three-year action plan to enhance the efficiency of medical insurance fund settlement, aiming to complete annual settlements by March 31 each year starting in 2028, with settlement funds accounting for about 3% of the annual medical insurance fund allocation [2] - This plan represents a systemic reform of the medical insurance system, addressing issues such as slow reimbursements for insured individuals and funding for medical institutions in the short term, while promoting scientific and refined management of medical insurance funds in the medium term [2] Medical Device Registration - The Deputy Director of the National Medical Products Administration, Lei Ping, attended a regional meeting on medical device registration management and conducted field research in Guangdong and Yunnan, emphasizing the need to align with the health demands of the people and plan for high-quality development in the medical device sector [3] Company Announcements - Jiukang Bio has received a medical device registration certificate for its fructosamine testing kit, which is expected to enhance its competitiveness in the in vitro diagnostic market, although future sales remain uncertain [5] - Yihuilong has obtained registration for its anti-phosphatidylserine/prothrombin IgM and IgG antibody testing kits, which will expand its product line in the autoimmune disease testing sector, with sales dependent on market conditions [6] - Kangzheng Pharmaceutical announced that its oral JAK1 inhibitor, Povorcitinib, has been included in the "Breakthrough Therapy" list for treating non-segmental vitiligo in adults [7] Capital Market Activities - Fosun Pharma plans to invest a total of 1.412 billion yuan in Green Valley Pharmaceutical, acquiring a 53% stake through its subsidiary [9] - Paig Bio Pharma-B has announced a further extension of the lock-up period for cornerstone investors until April 30, 2026, and is raising approximately 296 million HKD for various strategic initiatives [10] Industry Developments - A new medical health equity investment fund has been established in Nanjing with a total investment of 800 million yuan, focusing on private equity investments and asset management [12] - Zhenghai Bio has signed a 12 million yuan technology development contract with the Chinese Academy of Agricultural Sciences for the research and development of recombinant type III collagen products [13] - Beijing Weisi Weixiang Medical Technology Co., Ltd. has been established with a registered capital of 15 million yuan, focusing on the development and manufacturing of service robots [14] - Tongrentang Health has taken action against a product falsely labeled as produced by its subsidiary, initiating legal proceedings to protect consumer rights [15]

证券日报网讯 12月15日晚间，正海生物发布公告称，公司于近日与受托方中国农业科学院生物技术研 究所（简称"中国农科院生物所"）签署了关于"重组Ⅲ型胶原蛋白产品的研究开发"项目的《技术开发合 同》。合同总金额为1，200万元，将按照合同约定的里程碑节点进行具体支付。本次合同的签订无需提 交公司董事会、股东会审议。 （编辑 任世碧） ...

Group 1 - Shareholder Zhang Yu of Kehua Holdings plans to reduce his stake by up to 3%, amounting to no more than 5.83 million shares within three months [1] - Shanghai Ailu has signed a strategic cooperation agreement with Southern Road Machinery to provide packaging products for the dry-mixed mortar industry [2] - Xingyuan Zhuomei appointed Gong Chunming as the new deputy general manager [3] Group 2 - Tongyi Zhong's shareholder has set a preliminary transfer price of 15.47 yuan per share for a total of 4.27 million shares [4] - Anada's shareholder did not implement the planned share reduction of up to 2% by the deadline [5] - Rongchang Bio plans to repurchase shares worth between 20 million to 40 million yuan at a price not exceeding 95 yuan per share [6] Group 3 - Hainan Airport reported an 8.16% year-on-year increase in passenger throughput for November, totaling 2.09 million passengers [7] - Lanjian Intelligent plans to apply for a bank credit line of up to 1.2 billion yuan for various financial operations [8] - Xinlei Co. received a total of 561.43 million yuan in land acquisition and compensation payments [9] Group 4 - Foster reported a surplus of 321 million yuan from four fundraising projects, which will be used to supplement working capital [10] - China Southern Airlines experienced a 10.42% year-on-year increase in passenger turnover for November [12] - China National Airlines reported a 10.1% year-on-year increase in passenger turnover for November [17] Group 5 - Sanyou Chemical plans to register and issue mid-term notes not exceeding 1.3 billion yuan [18] - Quanyuan Spring used 60 million yuan of idle funds to purchase structured deposits [19] - Su Keng Agricultural Development appointed Zou Yi as the new deputy general manager [20] Group 6 - Jingneng Real Estate received approval to register mid-term notes totaling up to 2 billion yuan [21] - Dechang Co. received approval from the CSRC for a targeted issuance of shares [23] - Jiufeng Bio obtained a medical device registration certificate for its fructosamine testing kit [24] Group 7 - Jinzi Ham's president Guo Bo resigned for personal reasons, while Zheng Hu was appointed as the new president [25] - China Eastern Airlines reported a 10.35% year-on-year increase in passenger turnover for November [26] - Fengfan Co.'s controlling shareholder is in the process of acquiring 17.32% of the company's shares [27] Group 8 - Zhenghai Bio signed a technical development contract with the Chinese Academy of Agricultural Sciences for a collagen product project worth 12 million yuan [28] - Xinhua Insurance reported a 16% year-on-year increase in cumulative original insurance premium income for the first 11 months [29] - Jingjia Microelectronics' subsidiary completed key stages of its AI SoC chip project [30] Group 9 - Shanghai Pharmaceuticals' hydrochloride sotalol tablets passed the consistency evaluation for generic drugs [31] - Heshun Technology's subsidiary's carbon fiber project has entered a stable operational phase [32] - Spring Airlines reported an 18.02% year-on-year increase in passenger turnover for November [33] Group 10 - Huaxin New Materials proposed a mid-term dividend plan of 1 yuan per 10 shares [34] - Keda Li plans to increase capital by 300 million yuan for its wholly-owned subsidiary [35] - Jinguang Electric won a bid for a high-voltage direct current transmission project worth 84.86 million yuan [36] Group 11 - XGIMI Technology's subsidiary received a development notification for a vehicle-mounted projection project from a well-known domestic automotive manufacturer [37]

格隆汇12月15日丨正海生物(300653.SZ)公布，为进一步丰富公司的研发管线，扩充产品矩阵，公司于 近日与受托方中国农业科学院生物技术研究所（简称"中国农科院生物所"）签署了关于"重组III型胶原 蛋白产品的研究开发"项目的《技术开发合同》。合同总金额为1,200万元，将按照合同约定的里程碑节 点进行具体支付。 ...

正海生物（300653）(300653.SZ)公告，公司近日与受托方中国农业科学院生物技术研究所(简称"中国农 科院生物所")签署了关于"重组III型胶原蛋白产品的研究开发"项目的《技术开发合同》。合同总金额为 1200万元。 ...

智通财经APP讯，正海生物(300653.SZ)公告，公司近日与受托方中国农业科学院生物技术研究所(简 称"中国农科院生物所")签署了关于"重组III型胶原蛋白产品的研究开发"项目的《技术开发合同》。合 同总金额为1200万元。 ...

关于签订技术开发合同的公告 证券代码：300653 证券简称：正海生物 公告编号：2025-047 烟台正海生物科技股份有限公司 关于签订技术开发合同的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次签署的技术开发合同确立了双方的合作计划，具体实施进度和最终成果尚 存在不确定性，敬请广大投资者谨慎决策，注意投资风险。 2、本次技术开发合同的签署不会对公司本年度财务状况及经营业绩构成重大影响。 一、合同签署概况 为进一步丰富公司的研发管线，扩充产品矩阵，公司于近日与受托方中国农业科学 院生物技术研究所（以下简称"中国农科院生物所"）签署了关于"重组III型胶原蛋白 产品的研究开发"项目的《技术开发合同》。合同总金额为1,200万元，将按照合同约定 的里程碑节点进行具体支付。 根据相关规定，该事项不构成关联交易，不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。根据《深圳证券交易所创业板股票上市规则》《公司章程》等相 关规定，本次合同的签订无需提交公司董事会、股东会审议。 二、交易对手方介绍 乙方（受托方） 名称：中国农业科学院 ...

关于取得医疗器械注册变更文件的公告 证券代码：300653 证券简称：正海生物 公告编号：2025-046 烟台正海生物科技股份有限公司 关于取得医疗器械注册变更文件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 2、对产品技术要求相关内容进行变更。 上述变更文件与"国械注准 20143132108"注册证共同使用。 二、对公司的影响及风险提示 上述医疗器械注册证的变更符合公司发展需要，可进一步满足客户需求，有 利于公司业务开拓。本次变更对公司近期经营不会产生重大影响，敬请广大投资 者谨慎决策，注意防范投资风险。 特此公告。 烟台正海生物科技股份有限公司 烟台正海生物科技股份有限公司（以下简称"公司"）于近日取得由国家药 品监督管理局颁发的 1 项《医疗器械变更注册（备案）文件》，公司完成产品"皮 肤修复膜"的规格型号及产品技术要求的变更，现将相关情况公告如下： 一、该医疗器械的基本信息 | 产品名称 | 注册证编号 | 注册证有效期 | | | | 注册分类 | 适用范围 | | --- | --- | --- | --- | --- | --- | ...

Market Overview - The Shanghai Composite Index closed at 3870.02 points, above the six-month moving average, with a gain of 0.87% [1] - The total trading volume of A-shares reached 182.62 billion yuan [1] Stocks Breaking the Six-Month Line - A total of 290 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Xunxing Co., Ltd. (002098) with a deviation rate of 9.03% and a daily increase of 10.04% [1] - Meino Energy (001299) with a deviation rate of 8.16% and a daily increase of 9.98% [1] - Laimu Co., Ltd. (603633) with a deviation rate of 7.83% and a daily increase of 8.70% [1] Detailed Stock Performance - The following stocks have notable performance metrics: - Xunxing Co., Ltd. (002098): Latest price 10.08 yuan, half-year line 9.24 yuan, turnover rate 3.52% [1] - Meino Energy (001299): Latest price 13.00 yuan, half-year line 12.02 yuan, turnover rate 6.41% [1] - Laimu Co., Ltd. (603633): Latest price 10.87 yuan, half-year line 10.08 yuan, turnover rate 7.02% [1] - Other stocks with significant performance include: - Xinhua Pharmaceutical (000756) with a daily increase of 10.00% and a deviation rate of 6.41% [1] - Tonghe Technology (300491) with a daily increase of 7.25% and a deviation rate of 6.40% [1]